Clinical activity of sorafenib and sunitinib in renal cell carcinoma refractory to previous vascular endothelial growth factor-targeted therapy: Two case reports

Clinical Genitourinary Cancer

Volumn 5, Issue 1, 2006, Pages 78-81

  Shaheen, Philip E ^a   Rini, Brian I ^a   Bukowski, Ronald M ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

Angiogenesis; Metastases; Platelet derived growth factor; Tyrosine kinase inhibitors

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; INTERLEUKIN 2; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE; SORAFENIB; SUNITINIB; THALIDOMIDE; VASCULOTROPIN; ZOLEDRONIC ACID; ANTINEOPLASTIC AGENT; BENZENESULFONIC ACID DERIVATIVE; INDOLE DERIVATIVE; PYRIDINE DERIVATIVE; PYRROLE DERIVATIVE; VASCULOTROPIN RECEPTOR;

ADULT; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFICACY; DRUG MEGADOSE; DRUG TARGETING; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FATIGUE; GASTROINTESTINAL DISEASE; HISTOPATHOLOGY; HUMAN; INHIBITION KINETICS; INTRAVENOUS PYELOGRAPHY; KIDNEY CARCINOMA; LAMINECTOMY; LIVER METASTASIS; LOW DRUG DOSE; LUNG METASTASIS; LUNG RESECTION; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHRECTOMY; OSTEOSYNTHESIS; PERIPHERAL NEUROPATHY; PHYSICAL EXAMINATION; PREOPERATIVE EVALUATION; PROTEIN FAMILY; SKIN DISEASE; SPINAL CORD COMPRESSION; SPINE METASTASIS; THORACOTOMY; THORAX RADIOGRAPHY; TUMOR VOLUME; DRUG ANTAGONISM; KIDNEY TUMOR; METASTASIS; MIDDLE AGED; PATHOLOGY;

ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, RENAL CELL; HUMANS; INDOLES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PYRIDINES; PYRROLES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR;

EID: 33749054909     PISSN: 15587673     EISSN: None     Source Type: Journal    
DOI: 10.3816/CGC.2006.n.021     Document Type: Article

References (9)

1. Gnarra JR, Tory K, Weng Y, et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 1994; 7:85-90.
2. Na X, Wu G, Ryan CK, et al. Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas. J Urol 2003; 170:588-592.
3. Kaelin WG Jr. The von Hippel-Lindau tumor suppressor gene and kidney cancer. Clin Cancer Res 2004; 10:6290S-6295S.
4. Rini BI, Small EJ. Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol 2005; 23:1028-1043.
5. Escudier B, Szczylik C, Eisen T, et al. Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). J Clin Oncol 2005; 23(16 suppl):380s
6. Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24:16-24.
7. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the Raf/MEK/Erk pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64:7099-7109.
8. Casanovas O, Hicklin DJ, Bergers G, et al. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005; 8:299-309.
9. Rini B, Rixe O, Bukowski R, et al. AG-013736, a multi-target tyrosine kinase receptor inhibitor, demonstrates anti-tumor activity in a phase 2 study of cytokine-refractory, metastatic renal call carcinoma (RCC). J Clin Oncol 2005; 23(16 suppl):380s